PACIFIC: Treating Primary Mediastinal Large B-cell Lymphoma
This study is looking at how effective Brentuximab Vedotin and Nivolumab are, both alone and when combined with other drugs (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone), for people with untreated Primary Mediastinal Large B-cell Lymphoma (PMBL). Brentuximab Vedotin is a targeted therapy that delivers a toxic agent to cancer cells with a specific marker (CD30 receptors). Nivolumab is an immunotherapy that helps your immune system fight cancer. To join, you must have PMBL with at least 1% CD30 expression in your tumor. The main goal is to see how many people have a complete response to the treatment. The study is currently not recruiting new participants.
- Study design
- This is an interventional study with a planned enrollment of 31 participants. It is a phase II trial, meaning it tests the effectiveness and safety of the treatments.
- What's involved
- Participants will receive Brentuximab Vedotin and Nivolumab, followed by a combination of these drugs with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone. Treatment cycles will continue for up to 8 cycles, with PET/CT scans to check for complete response.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed up after completing therapy, with complete response assessed up to 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04745949
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
Recruiting
PHASE2Ages 18+InterventionalTreatmentM.D. Anderson Cancer CenterInvestigator-initiated
~31 participants
Updated 2026-02-19 on ClinicalTrials.gov
What's tested:Brentuximab VedotinCyclophosphamideDoxorubicinNivolumabPrednisoneQuality-of-Life Assessment
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Complete response rate
Measured over At completion of therapy, assessed up to 2 years
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Ranjit Nair · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histopathologically confirmed diagnosis of PMBL
Require a CD30 expression level of 1% or greater in the tumor or tumor-infiltrating lymphocytes by local immunohistochemistry
No prior treatment except
A prior limited-field radiotherapy
A short course (up to 7 days) of glucocorticoids =\< 100 mg daily of prednisone equivalent which must cease prior to day 1 of cycle 1
Stage of patients: Stages II, III, IV, and stage I \>= 5 cm in the greatest dimension
Patient or durable power of attorney (DPA) for healthcare must be able to understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form
Age \>= 18 years at the time of signing the informed consent
Patients must have bi-dimensional measurable disease, as defined as radiographically apparent disease with the longest dimension of \>= 1.5 cm
Patients with performance status of =\< 3 (3 only allowed if decline in status is deemed related to lymphoma and felt potentially reversible by the treating physician)
Serum bilirubin \< 1.5 x ULN except in patients with Gilbert's syndrome as defined by \> 80% unconjugated bilirubin
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN or \< 5 x ULN if hepatic metastases are present
Absolute neutrophil count (ANC) \> 1000/mm\^3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician
Platelets \> 1000/mm\^3 unless deemed related to lymphoma involvement in the bone marrow and felt potentially reversible by the treating physician
Calculated creatinine clearance \>= 30 ml/min by Cockcroft-Gault formula
Patients must be willing to receive transfusions of blood products
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \[beta-hCG\]) at screening
Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of birth control during and after the study (12 months for women and 3 months for men), consistent with local regulations regarding the use of birth control methods for subjects participating in this clinical study. Men must agree to not donate sperm during and for up to 3 months after their conclusion of therapy on study. For females, these restrictions apply for 1 month after the last dose of study drug
Exclusion
Patients with an urgent need for cytoreductive treatment will be excluded
Any serious medical condition including but not limited to uncontrolled hypertension, uncontrolled congestive heart failure within past 6 months prior to screening (class 3 \[moderate\] or class 4 \[severe\] cardiac disease as defined by the New York Heart Association Functional Classification), uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), left ventricular ejection fraction (LVEF) less than 40%, renal failure, active infection, history of invasive fungal infection, moderate to severe hepatic disease (Child Pugh class B or C), active hemorrhage, laboratory abnormality, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form. Patients with history of cardiac arrhythmias should have cardiac evaluation and clearance
Previous anthracycline exposure with expected lifetime exposure to doxorubicin \> 450 mg/m\^2, considering the planned anthracycline exposure in this study with potential six cycles of R-CHP
Pregnant or lactating females
Known hypersensitivity to brentuximab vedotin, nivolumab, rituximab, doxorubicin, cyclophosphamide, or prednisone
Known human immunodeficiency virus (HIV) infection with active viremia
Patient with known HIV infection can be included if undetectable viral load, CD4 \>= 300 cells/microL and on HAART (highly active antiretroviral therapy)
Patients with active viremia of hepatitis B infection
Not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody
Patients with active viremia of hepatitis C infection
Known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
All patients with central nervous system involvement with lymphoma
Diagnosis of prior malignancy within the past 2 years with the exception of successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast. History of other malignancies are allowed if in remission (including prostate cancer patients in remission from radiation therapy, surgery or brachytherapy), not actively being treated, with a life expectancy \> 3 years
Significant neuropathy (grades 2 or grade 1 with pain) within 14 days prior to enrollment
Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to lymphoma
Major surgery within 4 weeks of study entry or wound that is not healed from prior surgery or trauma
History of stroke or intracranial hemorrhage within 6 months prior to study entry
Vaccinated with live, attenuated vaccines within 4 weeks of study entry
What this trial measures
- Complete response rateAt completion of therapy, assessed up to 2 years
Will be defined as the percentage of number of complete responses in total number of patients treated, which includes all the patients who were treated, even the patients dropped out at interim positron emission tomography/computed tomography scan after cycle 4 due to stable disease/progressive disease. Simon's optimal two-stage design will be used. Fisher's exact test will be used to evaluate the association between response and other categorical patient variables. T-test or Wilcoxon rank sum test will be used to evaluate the difference in continuous variables between responders and non-responders.